<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819220</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0077</org_study_id>
    <nct_id>NCT01819220</nct_id>
  </id_info>
  <brief_title>Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have demonstrated that RAS inhibitors/calcium channel blockers are superior to&#xD;
      RAS inhibitors/diuretics for reducing cardiovascular outcomes in hypertension. As such, RAS&#xD;
      inhibitors/calcium channel blockers are recommended as first line combination treatment for&#xD;
      hypertension. However, the mechanism for the superior efficacy of RAS inhibitors/calcium&#xD;
      channel blockers are not well defined. This study will compare the efficacy of RAS&#xD;
      inhibitors/calcium channel blockers vs RAS inhibitors/diuretics in terms of glucose tolerance&#xD;
      and insulin resistance in hypertensive patients with metabolic syndrome. The primary endpoint&#xD;
      will be that RAS inhibitors/calcium channel blockers will be more efficacious in reducing&#xD;
      2hour post prandial glucose compared to RAS inhibitors/diuretics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the glucose change</measure>
    <time_frame>To assess the change from baseline (week 0) to study endpoint (week 24) on 2hr-post-prandial plasma glucose level using oral glucose tolerance test (75-g OGTT)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>amlodipine/valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrochlorothiazide/telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/valsartan</intervention_name>
    <description>This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.&#xD;
Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.&#xD;
When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.</description>
    <arm_group_label>amlodipine/valsartan</arm_group_label>
    <other_name>Starting dose of amlodipine 5mg/ valsartan 80mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide/telmisartan</intervention_name>
    <description>When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.&#xD;
When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.</description>
    <arm_group_label>hydrochlorothiazide/telmisartan</arm_group_label>
    <other_name>Telmisartan 40mg/hydrochlorothiazide 12.5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  consent to the study&#xD;
&#xD;
          -  Male or Female ≥ 20 years&#xD;
&#xD;
          -  Patients taking less than 1 antihypertensive medications or not taking&#xD;
             antihypertensive medications. Hypertension defined at the screening visit as follows):&#xD;
             140mmHg &lt; MSSBP or MSDBP &gt; 90mmHg at screening&#xD;
&#xD;
          -  Hypertensive patients with non diabetic metabolic syndrome will be enrolled. Metabolic&#xD;
             syndrome is defined according to NCEP guideline. (3 or more than) ① Abdominal obesity:&#xD;
             Waist circumference M ≥ 90cm, F ≥ 80cm&#xD;
&#xD;
             ② Hypertriglyceridaemia: Triglycerides ≥ 150mg/dL&#xD;
&#xD;
             ③ Low HDL cholesterol Men: HDL cholesterol ≤ 40mg/dL Women: HDL cholesterol ≤ 50mg/dL&#xD;
&#xD;
             ④ Elevated blood pressure (systolic blood pressure ≥ 130 mmHg and diastolic blood&#xD;
             pressure ≥ 85 mmHg, or current use of antihypertensive drugs)&#xD;
&#xD;
             ⑤ Impaired fasting glucose: fasting plasma glucose ≥ 100 mg/dL&#xD;
&#xD;
          -  Patient not taking statin medication and if the patient had ate statin medication the&#xD;
             last duration must be before 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Women of child-bearing potential without a contraceptive measure&#xD;
&#xD;
               -  (Pregnant or nursing women&#xD;
&#xD;
               -  Known or suspected contraindications: history of allergy or hypersensitivity&#xD;
&#xD;
               -  History of clinically significant allergies including asthma and/or multiple drug&#xD;
                  allergies&#xD;
&#xD;
               -  Patients taking more than 2 antihypertensive medications&#xD;
&#xD;
               -  Patient taking statin medication and taking statin within 3 months&#xD;
&#xD;
               -  MSSBP &gt; 180 mmHg or MSDBP &gt; 110 mmHg at any time during the study&#xD;
&#xD;
               -  Evidence of a secondary form of hypertension)&#xD;
&#xD;
               -  History of hypertensive encephalopathy, cerebrovascular accident, transient&#xD;
                  ischemic attack, myocardial infarction, percutaneous coronary intervention (PCI)&#xD;
                  or coronary artery bypass graft surgery (CABG) for 12 months prior to Visit 1&#xD;
&#xD;
               -  History of heart failure Grade II - IV according to the NYHA classification&#xD;
&#xD;
               -  Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia&#xD;
&#xD;
               -  Concomitant unstable angina pectoris&#xD;
&#xD;
               -  Clinically significant valvular heart disease&#xD;
&#xD;
               -  Patients with Type 1 or Type 2 diabetes mellitus&#xD;
&#xD;
               -  Evidence of hepatic disease as determined by one of the following: AST or ALT&#xD;
                  values ≥ 3 x UNL, a history of hepatic encephalopathy, history of esophageal&#xD;
                  varices, or history of portocaval shunt&#xD;
&#xD;
               -  Evidence of renal impairment as determined by one of the following: serum&#xD;
                  creatinine &gt;2mg/dL , history of dialysis, or history of nephrotic syndrome&#xD;
&#xD;
               -  Protein in U/A values 2+ ≤&#xD;
&#xD;
               -  Serum potassium values &lt; 3.2 or &gt; 5.2 mmol/L&#xD;
&#xD;
               -  History of malignancy of any organ system within the past 5 years, treated or&#xD;
                  untreated, including leukemia and lymphoma, as further defined in the full&#xD;
                  protocol&#xD;
&#xD;
               -  Chronic use of NSAIDs&#xD;
&#xD;
               -  Use of cyclooxygenase-2 inhibitors (COX-2 inhibitors&#xD;
&#xD;
               -  Use of niacin &gt; 100 mg/d&#xD;
&#xD;
               -  Use of loop diuretics&#xD;
&#xD;
               -  Use of statin shorter than 3 months&#xD;
&#xD;
               -  Inability to discontinue prior antihypertensive drugs as specified in the full&#xD;
                  protocol&#xD;
&#xD;
               -  persons directly involved in the execution of this protocol&#xD;
&#xD;
               -  Volume depletion based on the investigator's clinical judgment using vital signs,&#xD;
                  skin turgor, moistness of mucous membranes, and laboratory values&#xD;
&#xD;
               -  Any severe, life-threatening disease within the past five years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei universty medical center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>March 15, 2013</study_first_submitted>
  <study_first_submitted_qc>March 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
    <mesh_term>Telmisartan, hydrochlorothiazide drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

